Drug Research

Allena Pharmaceuticals Completes Animal Proof-of-Concept Study for ALLN-346, Lead Product Candidate for Hyperuricemia in the Setting of Advanced Chronic Kidney Disease

June 19, 2018

NEWTON, Mass., June 19, 2018 (GLOBE NEWSWIRE) — Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the completion of an animal proof-of-concept study supporting the selection of ALLN-346 as its lead product candidate […]

Cold Agglutinin Disease Associated with Greater Than Twofold Increased Risk of Mortality in First Five Years After Diagnosis

June 18, 2018

WALTHAM, Mass.–(BUSINESS WIRE)–Bioverativ Inc., a Sanofi company dedicated to transforming the lives of people with rare blood disorders, today announced results from a new, population-based retrospective study that found a greater than twofold increased risk of mortality in people with cold agglutinin disease (CAD) within the first five years after diagnosis. The study, which is […]

Clinical Epidemiologist, Mathematician, Open Science & Blockchain Enthusiast Dr. Mehdi Benchoufi Joins Saama Advisory Board

June 18, 2018

CAMPBELL, CA — (June 18, 2018) – Saama Technologies, Inc., a leading big data and advanced analytics solutions company, today announced that Mehdi Benchoufi, M.D., Assistant Professor in the Clinical Epidemiology Center at Hôtel-Dieu Hospital, University Paris Descartes, has joined its Board of Advisors(BOA). Dr. Benchoufi focuses on interfaces between clinical research and open technologies, with a […]

AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress

June 15, 2018

NORTH CHICAGO, Ill., June 15, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the presentation of investigational data from a new analysis of undetectable minimal residual disease (uMRD) rates from the pivotal Phase 3 MURANO trial of venetoclax, a first-in-class oral B-cell lymphoma-2 (BCL-2) inhibitor, in combination with rituximab (VenR) […]

Amphivena Demonstrates at EHA First Human Proof-of-Concept For AMV564 in Relapsed/Refractory AML

June 15, 2018

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Amphivena Therapeutics today highlighted initial data from the dose-escalation portion of the First-in-Human Phase 1 trial (AMV564-101, NCT03144245) evaluating AMV564 in patients with relapsed and/or refractory acute myeloid leukemia (AML) in an oral presentation at the 23rd European Hematology Association (EHA) meeting in Stockholm (Abstract S859). The data from 17 patients […]

TG Therapeutics, Inc. Announces Oral Presentation of Umbralisib plus Ruxolitinib in Patients with Myelofibrosis at the 23rd Congress of the European Hematology Association

June 15, 2018

NEW YORK, June 15, 2018 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ:TGTX), today announced updated clinical data from its ongoing Phase I study evaluating umbralisib (TGR-1202), the Company’s PI3K delta inhibitor in combination with ruxolitinib, the JAK 1/2 inhibitor, in ruxolitinib experienced patients with myelofibrosis (MF). Data from this trial are being presented this morning […]

Stemline Therapeutics Announces Presentation of ELZONRIS™ (tagraxofusp; SL-401) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress

June 15, 2018

NEW YORK, June 15, 2018 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that ELZONRIS™ (tagraxofusp; SL-401) preclinical data in the autoimmune disorder systemic sclerosis were delivered via poster presentation at the Annual European Congress of Rheumatology (EULAR) in Amsterdam. The poster, entitled “SL-401, a Novel […]

Certara Supports the Not-for-profit Biotechnology Company Medicines Development for Global Health (MDGH) on the FDA New Drug Approval of Moxidectin for the Treatment of River Blindness (Onchocerciasis), a Neglected Tropical Disease

June 14, 2018

Certara was privileged to participate as a key member of the Medicines Development for Global Health development team to achieve FDA approval of moxidectin Certara®, the global leader in model-informed drug development, regulatory science, market access and real-world evidence services, today celebrated an important milestone for its public health drug development and treatment consulting portfolio. […]

Atara Biotherapeutics Announces Publication of New Research Linking Epstein-Barr Virus (EBV) Infection and Multiple Sclerosis (MS)

June 13, 2018

SOUTH SAN FRANCISCO, Calif., June 13, 2018 (GLOBE NEWSWIRE) — Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced publication of new research findings advancing the understanding of Epstein-Barr Virus (EBV) infection in the multiple sclerosis (MS) brain. The research […]

Synlogic Presents Preclinical Data from Synthetic BioticTM Medicine, SYNB1618, for the Treatment of Phenylketonuria

June 12, 2018

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, today announced the presentation of preclinical data from SYNB1618, an investigational Synthetic Biotic medicine currently being evaluated in an ongoing Phase 1/2a clinical trial in healthy volunteers and patients with PKU. The […]

GenScript Supports the Development of a Novel HIV Vaccine

June 12, 2018

PISCATAWAY, N.J., June 12, 2018 /PRNewswire/ — A promising experimental HIV vaccine was reported in Nature Medicine on June 4, 2018 by Kai Xu and colleagues from Drs. Mascola and Kwong labs at the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health […]

Chimerix Announces Discovery and Demonstrated Preclinical Activity Supporting Ongoing Phase 1 Study of New Antiviral for Treatment and Prevention of Norovirus

June 12, 2018

DURHAM, N.C., June 12, 2018 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced results from preclinical studies supporting further evaluation of CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus. CMX521 showed activity in vitro against all strains of norovirus tested, […]

Orig3n Announces Osteoarthritis Cartilage Regeneration for First Cell Therapy Program

June 11, 2018

BOSTON, June 8, 2018 /PRNewswire/ — Orig3n, a Boston-based biotech company pioneering the future of health through genetics and regenerative medicine, today announced its focus on osteoarthritis indications for its Cartilage Regeneration Program, the company’s first iPS-derived cell therapy program. According to the Arthritis Foundation, arthritis is the leading cause of disability among adults in […]

Achieve Announces Publication of Cytisine Data for Next-Generation Cytisine Molecules

June 11, 2018

SEATTLE and VANCOUVER, British Columbia, June 11, 2018 /PRNewswire/ — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that cytisine data, generated in collaboration with the University of Bristol, was published in Chem. These data show that via the […]

MANF Therapeutics Announces Independent Publication of Positive Data for MANF in Traumatic Brain Injury Animal Model

June 11, 2018

NEW YORK, June 11, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE–MANF Therapeutics, Inc., a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS) in pre-clinical development advancing the orphan-drug designated therapeutic protein mesencephalic astrocyte-derived neurotrophic factor (MANF) as a disease-modifying treatment for orphan ophthalmological conditions, Glaucoma and Parkinson’s disease, today announced the publication of a […]

Therapeutic Solutions International Expands Adoptive Immunotherapy Portfolio by Incorporation of “Universal Cancer Antigen” into StemVacs Dendritic Cell Platform

June 11, 2018

OCEANSIDE, Calif., June 11, 2018 (GLOBE NEWSWIRE) — Via OTC PR Wire –Therapeutics Solutions International, Inc., (OTC Markets:TSOI) announced today initiation of efforts to combine its existing CTCFL “universal cancer antigen”, labeled as BRS-001, with its clinical stage StemVacs Dendritic Cell Platform. The Company previously filed a patent on technologies covering novel means of stimulating […]

Saama Launches Deep Learning Intelligent Assistant (DaLIA) to Solve Clinical Development Pain Points

June 11, 2018

Saama Launches Deep Learning Intelligent Assistant (DaLIA) to Solve Clinical Development Pain Points AI-Informed Virtual Assistant Elevates Functionality of Existing Clinical Trial Solutions CAMPBELL, CA – (June 11, 2018) – Saama Technologies, Inc., a leading data analytics company, today announced the launch of a unique set of Artificial Intelligence (AI) capabilities specifically designed to alleviate […]

Wasdell Group invests £500k in new microbiological and analytical lab

June 7, 2018

The Wasdell Group (Wasdell), a leading outsourcing partner to companies within the pharmaceutical, medical device and clinical trials industries, is investing £500k in a new laboratory at its Newcastle site. The purpose built 1,200 sq. ft facility will allow Wasdell to offer in-house microbiological and analytical services to its customers and will support the business’ […]

BioIVT to Host Webinar Describing In Vitro Models to Predict Herb-Drug Interactions

June 6, 2018

These in vitro models can help to identify herbal ingredients with the potential to alter the safety or efficacy of prescription drugs   BioIVT, a leading provider of biospecimens and related services, today announced that it will be hosting a webinar entitled “Whole-cell In Vitro Models Can Predict Clinically-relevant Herb-Drug Interactions (HDIs)” at 11 am […]

Landos Biopharma Announces Human Translational Results for Mechanisms of BT-11 in IBD at Digestive Disease Week 2018

June 6, 2018

BLACKSBURG, Va. & WASHINGTON–(BUSINESS WIRE)–Landos Biopharma, Inc., an emerging biopharmaceutical company focused on developing improved treatments for autoimmune diseases presented findings from mechanisms of action studies for its lead candidate, BT-11 in models of Crohn’s disease (CD) and Ulcerative Colitis (UC) at Digestive Disease Week 2018. The studies demonstrate that through the activation of the […]

Following historical budget allocation, Canada enters BIO 2018 with thriving life science industry

June 6, 2018

Following historical budget allocation, Canada enters BIO 2018 with thriving life science industry Contact: Brendan Monahan Rasky Partners, Inc. bmonahan@rasky.com 413-537-4063 Boston, Ma (June 1st, 2018) –The size and prominence of the Canadian delegation arriving at BIO 2018 – among the largest international delegation – demonstrates the tremendous success that the government’s record setting investment […]

Certara Launches Version 8.1 of its Industry-leading Phoenix PK/PD Modeling and Simulation Software; Introduces Professional Certification Program

June 5, 2018

Certara provides scientists with automated, comprehensive tools for PK/PD analysis and modeling, and announces industry’s first PK/PD certification program for Phoenix software in partnership with Credly Certara®, the global leader in model-informed drug development, regulatory science, market access and real-world evidence services, today announced the launch of Phoenix® 8.1. Phoenix is the most advanced and […]

Enhance Precision Oncology Trial Success

June 4, 2018

As the complexity of precision oncology trials increase, drug developers are facing the paradox of patient scarcity in the presence of data abundance. Using the right technologies can help to solve this paradox. Read our white paper to learn more.  

Aptose Announces Two Publications of Preclinical Data Elucidating the Anticancer Mechanism of Action of APTO-253

June 4, 2018

SAN DIEGO and TORONTO, June 04, 2018 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced the publication of preclinical data elucidating the mechanism of action of APTO-253, the company’s clinical stage anticancer product candidate. The data are published in two separate articles in the June 2018 issue (Volume 17, Number 6) of Molecular […]

FEEDBACK